Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in nonalcoholic fatty liver disease

Kanwal, Fasiha, Kramer, Jennifer R., Li, Liang, Dai, Jianliang, Natarajan, Yamini, Yu, Xian, Asch, Steven M., El‐Serag, Hashem B.·2020·Hepatology
DOI 10.1002/hep.31014

Cited by (320)

Items 201–300 of 320

  1. Impact of Diabetes Mellitus and Obesity Comorbidities on Survival Outcomes after Hepatocellular Carcinoma Resection: A Multicenter Retrospective Study
    Hiroji Shinkawa, Masaki Kaibori, Masaki Ueno, Satoshi Yasuda, Hisashi Ikoma, Tsukasa Aihara, Takuya Nakai, Masahiko Kinoshita, Hisashi Kosaka, Shinya Hayami et al. · 2024 · Liver Cancer
  2. Cost-Utility Analysis of Noninvasive Tests to Initiate Hepatocellular Carcinoma Surveillance in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Pakanat Decharatanachart, Kittiyod Poovorawan, Pisit Tangkijvanich, Phunchai Charatcharoenwitthaya, Thoetchai Bee Peeraphatdit, Suthira Taychakhoonavudh, Sombat Treeprasertsuk, Roongruedee Chaiteerakij · 2025 · The American Journal of Gastroenterology
  3. Steatotic liver disease trajectory: A holistic EASL guidance on the multidisciplinary approach to screening and patient management
    Willem Pieter Brouwer, Luisa Vonghia, Maja Sofie Thiele, Jörn Markus Schattenberg, Foteini Anastasiou, Sonja Beckmann, Elisabetta Bugianesi, Laurent Castéra, Cyrielle Caussy, Ahmed Cordie et al. · 2026 · JHEP Reports
  4. Expert Panel Consensus on Clinical Assertion Statements Describing Noninvasive Tools for Diagnosing Nonalcoholic Steatohepatitis
    Ira M. Jacobson, Vincent Wai‐Sun Wong, Laurent Castéra, Quentin Mark Anstee, Mazen Noureddin, Kenneth J. Cusi, Stephen A. Harrison, Elisabetta Bugianesi, Zobair M. Younossi · 2022 · Journal of Clinical Gastroenterology
  5. Metabolic dysfunction-associated steatotic liver disease: a key factor in hepatocellular carcinoma therapy response
    Camilo Julio Llamoza-Torres, María Fuentes-Pardo, Bruno Ramos‐Molina · 2024 · Metabolism and Target Organ Damage
  6. Mechanisms and immunotherapies of HBV- and NAFLD-related hepatocellular carcinoma
    Xiaojia Song, Chunhong Ma · 2020 · Hepatoma Research
  7. Contrast-enhanced ultrasound and its differential diagnosis in 21 patients with intrahepatic space-occupying lesions under the background of fatty liver
    Yuqun Luo, Wensheng Yue, Zukun Li, Ping Wang · 2021 · Annals of Palliative Medicine
  8. Clinical implications of hepatic structure and function evaluation based on vibration-controlled transient elastography and liver maximum function capacity test in patients with nonalcoholic fatty liver disease
    Valentin Blank, David Petroff, Albrecht Boehlig, Aileen Heinze, Thomas Karlas, Thomas Berg, Johannes Wiegand · 2022 · European Journal of Gastroenterology & Hepatology
  9. The probiotic Lacticaseibacillus rhamnosus SD11 alleviates the progression of liver and colon damage through modulation of inflammation and tight junction proteins in streptozotocin-induced diabetic mice
    Waraporn Ruathong, Pissared Khuituan, Saranya Peerakietkhajorn, Rawee Teanpaisan, Jongdee Nopparat · 2024 · PLoS ONE
  10. DiabetesLiver score: A non-invasive algorithm for advanced liver fibrosis and liver-related outcomes in type 2 diabetes mellitus population
    Chuan Liu, Jie Shen, Jie Li, Zhihui Li, Ming‐Hua Zheng, Hua Bian, Xiqiao Zhou, Wenjing Ni, Zhongji Meng, Jiaojian Lv et al. · 2025 · Med
  11. Decoding survival in MASLD: the dominant role of metabolic factors
    Zhi-Qiang Jin, Cheng Zeng, Yang Yang, Shan Zhong, Zhi Zhou · 2025 · Diabetology & Metabolic Syndrome
  12. Differential associations of cardiometabolic risk factors with liver-related events by alcohol consumption category: Results from a large population-based study
    Hongliang Xue, Liqing Wang, Yuankai Wu, Yingxin Liao, Shijia Wang, Ailan Chen, Sun On Chan, Wenhua Ling, Xu Chen, Chao Yu · 2025 · Hepatology
  13. Imaging in MASLD
    Sudhakar Kundapur Venkatesh · 2026 · Expert Review of Gastroenterology & Hepatology
  14. Diabetes Status and Pancreatic Cancer Survival in the Nationwide Veterans Affairs Healthcare System
    Natalia I. Khalaf, Jennifer R. Kramer, Yan Liu, Daniela Abrams, Hardeep Singh, Hashem B. El‐Serag, Fasiha Kanwal · 2023 · Digestive Diseases and Sciences
  15. Lifestyle and genetic risk of chronic liver disease in metabolically healthy and unhealthy individuals from the general population
    Isabel Drake, Alice Giontella, Mariam Miari, Kristina Önnerhag, Marju Orho‐Melander · 2024 · JHEP Reports
  16. Derivation and validation of the BIMAST score for predicting the presence of fibrosis due to Metabolic dysfunction-associated steatotic liver disease among diabetic patients in the community
    Roberta Forlano, Tijana Stanic, Sahan Jayawardana, Benjamin Harvey Mullish, Michael S. Yee, Elias A. Mossialos, Robert David Goldin, Salvatore Petta, Emmanuel A. Tsochatzis, Mark R. Thursz et al. · 2024 · PLoS ONE
  17. Interplay Between Fatty Acids, Stearoyl-Co-A Desaturase, Mechanistic Target of Rapamycin, and Yes-Associated Protein/Transcriptional Coactivator With PDZ-Binding Motif in Promoting Hepatocellular Carcinoma
    Jihane N. Benhammou, Jim Sinnett-Smith, Joseph R. Pisegna, Enrique Rozengurt · 2022 · Gastro Hep Advances
  18. Investigating the Effect of Metabolic Phenotypes on Health Events in Alcoholic and Nonalcoholic Fatty Liver Disease
    Hong Xia Fan, Pengyan Zhang, Zhenqiu Liu, Renjia Zhao, Chen Suo, Xingdong Chen, Tiejun Zhang · 2023 · Journal of Clinical and Translational Hepatology
  19. Prospects of using sodium-glucose co-transporter-2 (SGLT-2) inhibitors in patients with metabolic-associated fatty liver disease (MAFLD)
    Iryna Oleksandrivna Kostitska, Nadia Protas, Liliia Petrovska · 2023 · Diabetes Obesity Metabolic Syndrome
  20. Indian Literature Review on Nonalcoholic Fatty Liver Disease
    R. Balamurali, Manimaran Murugesan, Chitra Shanmugam, Sathya Gopalsamy, Krishna Kumar Chinnadurai · 2023 · Gastroenterology Hepatology and Endoscopy Practice
  21. Hepatocellular carcinoma risk in ICD-coded non-cirrhotic nonalcoholic fatty liver disease refined by fatty liver index: A nationwide South Korean cohort study
    Chang Hun Lee, Min Gu Kang, Shinyoung Oh, In Sun Goak, Chen Shen, Ha Ram Oh, Young Ran Park, Jong Seung Kim, Ji Hyun Park · 2025 · Clinics and Research in Hepatology and Gastroenterology
  22. Frontiers in fatty liver: recent advances in pathogenic mechanisms, assessment of patients’ prognosis and pharmacotherapy
    Maite G. Fernández‐Barrena, Matias Antonio Avila · 2023 · Journal of Physiology and Biochemistry
  23. Association of Fasting C-Peptide to High Density Lipoprotein Cholesterol Ratio with Non-Alcoholic Fatty Liver Disease in Chinese Type 2 Diabetes Mellitus Patients: A Cross-Sectional Study
    Qian Liang, Haofei Hu, Xuan Chen, Shufen Yang, Ying Zhang, Yuhong Wu, Xinyu Wang, Hong Chen · 2025 · Diabetes Metabolic Syndrome and Obesity
  24. The role of primary care in response to the global liver disease syndemic: a Lancet Gastroenterology & Hepatology Commission
    Helen Jarvis, Paul Brennan, Teresa Casanovas, Kelly Casler, Monica Desai, Philip H Evans, John Francis Dillon, Ignazio Grattagliano, Kate Hallsworth, Vanessa Hebditch et al. · 2026 · The Lancet. Gastroenterology & hepatology
  25. Screening and diagnosis of liver disease in diabetes: a guide and evidence-based assessment
    Sami U. Qadri · 2026 · Diabetologia
  26. Dietary and nutrition considerations in caring for patients with nonalcoholic fatty liver disease: Updates for the practicing clinician
    Carolyn A. Newberry, Sonal Rajesh Kumar · 2022 · Nutrition in Clinical Practice
  27. Immune checkpoint inhibitor therapy for hepatocellular carcinoma
    Daryl Ramai · 2022 · Annals of Gastroenterology
  28. Effects of ranitidine and nizatidine on the risk of gastrointestinal cancer
    Hyejung Kang, Chung Mo Nam, Dong‐Woo Choi, Sohee Park · 2023 · Frontiers in Oncology
  29. Relevance of GLP-1 receptor agonists or SGLT-2 inhibitors on the recruitment for clinical studies in patients with NAFLD
    Michael Holzhey, David Petroff, Kerstin Wirkner, Christoph Engel, Ronny Baber, Anke Tönjes, Samira Zeynalova, Maryam Yahiaoui‐Doktor, Thomas Berg, Thomas Karlas et al. · 2023 · European Journal of Gastroenterology & Hepatology
  30. Characteristics of diabetes mellitus patients with nonviral chronic liver disease who developed hepatocellular carcinoma
    Kyo Sasaki, Miwa Kawanaka, Yasuyuki Tomiyama, Akinobu Takaki, Motoyuki Otsuka, Fusao Ikeda, Naoko Yoshioka, Hideaki Kaneto, Jun Wada, Tetsuya Fukuda et al. · 2024 · Hepatology Research
  31. Compensated advanced chronic liver disease in patients with metabolic dysfunction-associated steatotic liver disease: association with cardiometabolic factors
    Гомонова Вероника Павловна, K. L. Raikhelson, Пазенко Екатерина Владимировна, Прашнова Мария Константиновна, Sergey Vladimirovich Lapin, В. Д. Назаров, D. V. Sidorenko · 2024 · Sechenov Medical Journal
  32. Association between non-alcoholic fatty liver disease and arterial stiffness measured by brachial-ankle pulse wave velocity: a cross-sectional population study
    Yujie Wang, Zhicheng Fang, Qiuyue Fu, Dongai Yao, Xiaoqing Jin · 2025 · PeerJ
  33. Association between estimated glucose disposal rate and the risk of MAFLD in American adults: a cross-sectional study
    Yuhang Zhou, Bang Wang, Ming Wu, Han Hong, Gaochao Li, Minhui Xu · 2025 · Scientific Reports
  34. Letter to the Editor: Consider More Factors When Studying Risk of Cirrhosis and Hepatocellular Cancer in Patients With Nonalcoholic Fatty Liver Disease
    Naibin Yang, Guoxiang Li, Jinguo Chu, Yun‐Jing Wang · 2019 · Hepatology
  35. Screening for Non-alcoholic Fatty Liver Disease in Current Practice
    Margaret Spinosa, She-Yan Wong · 2021 · Current Hepatology Reports
  36. Analysis of the detection rate and related factors of fatty liver disease in physical examination of healthy population in Chengdu district
    Qian Han, Jiaojiao Guo, Ling Gong, Changqing Liu, Fan Zhang · 2023 · Medicine
  37. Da NAFLD a MASLD: pillole per endocrinologi
    Vincenza Di Stasi, Elisa Maseroli, Giovanni De Pergola, Linda Vignozzi · 2025 · L Endocrinologo
  38. A Systematic Review on Important Risk Factors and Possible Involved Mechanisms of Medicinal Plants on Nonalcoholic Fatty Liver Disease
    Amir Reza Rouhi-Boroujeni, Fatemeh Aliakbari, Ehsan Bakhshian-Dehkordi, Lotfolah Afzali, Hojjat Rouhi-Boroujeni · 2025 · Advanced Biomedical Research
  39. Cardiometabolic and genetic factors in the progression of metabolic dysfunction-associated steatotic liver disease
    Гомонова Вероника Павловна, K. L. Raikhelson · 2025 · Terapevticheskii arkhiv
  40. Reducing complications of metabolic dysfunction–associated steatotic liver disease
    Naohiro Wada, Michihiro Iwaki, Takashi Kobayashi, Atsushi Nakajima, Masato Yoneda · 2025 · Expert Review of Gastroenterology & Hepatology
  41. Metabolic-associated steatotic liver disease (MASLD): how I evolved my approach to diagnosis and staging
    Maria Kalafateli, Burcu Sena Aydin, Boran Polat, Michael S. Yee, Roberta Forlano, Chioma N. Izzi‐Engbeaya, Mark R. Thursz, Benjamin Harvey Mullish, Pinelopi Manousou · 2025 · Frontline Gastroenterology
  42. Association between cholecystectomy and the risk of new-onset metabolic dysfunction-associated steatotic liver disease: a risk-stratified cohort study
    Hong Jae Jeon, Hyuk Soo Eun, Woo Sun Rou, Seok Hyun Kim, Byung Seok Lee, Soon‐Ki Ahn · 2025 · Scientific Reports
  43. The Association Between Physical Activity, Sedentary Time, and Sleep with Risk of Hepatocellular Carcinoma in Patients with Cirrhosis
    Samuel Ma, Yossef Alsabawi, Fasiha Kanwal, Hao T. Duong, Laith El-Serag, Amit G. Singal, Nicole E. Rich, Saira Aijaz Khaderi, Sumeet K. Asrani, Hashem B. El‐Serag et al. · 2025 · Digestive Diseases and Sciences
  44. Predictive Value and Correlation Study of HOMA2 IR-CP and TyG-BMI for Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients with Type 2 Diabetes Mellitus
    Qiumei Cao, Qun Tian, Yu Liu, Yuzhu Cheng, Ting Luo, Xiaolin Zhu · 2025 · Diabetes Metabolic Syndrome and Obesity
  45. Pediatric MASLD: The New Era Practical Approach to Assessment and Treatment of Pediatric MASLD with Emphasis on Risk Factors and Obesity Medications
    Dieudonne Nonga, Eileen A. Chaves, Sindhu Pandurangi, Kayla T. Hartjes, Christopher Chu, Alvaro Flores · 2025 · Current Treatment Options in Pediatrics
  46. Metabolic features’ effect on FibroScan-AST (FAST) score in Egyptian patients with metabolic dysfunction-associated steatotic liver disease (MASLD)
    Amal Mohammed Dwidar, Ayat Ismail Ferra, Amany Mohamed Dwidar, Eslam Saber Esmail, Rania Mamdouh Elkafoury · 2026 · Egyptian Liver Journal
  47. Risk stratification for patients with MASLD based on cardiometabolic risk factors
    Yiheng Zhang, Yan Wang, Yaping Xu, Xu Liu, Yundong Qu, Tao Li · 2026 · BMC Public Health
  48. Impact of cardiometabolic criteria on the pathogenesis of MASLD and diagnostic performance of non-invasive tests
    Kazuhito Kawata, Hirokazu Takahashi, Taeang Arai, Yuya Seko, Takeshi Chida, Hidenao Noritake, Hidenori Toyoda, Hideki Hayashi, Kanji Yamaguchi, Michihiro Iwaki et al. · 2026 · Journal of Gastroenterology
  49. Metabolically associated fatty liver disease: What hepatologists need to know about this systemic disease
    Alexander L. PLAKIDA, Ольга Юшковська, Lidia Elżbieta Sierpińska · 2026 · World Journal of Hepatology
  50. Current management of MASLD in type 2 diabetes
    Valeria Michelle Fernández‐Garibay, Vianney Sarabia-Chao, Norberto Carlos Chávez-Tapia · 2026 · HORMONES
  51. Contemporary epidemiology of metabolic dysfunction-associated steatotic liver disease
    Do Han Kim, Donghyun Ko, Aijaz Ahmed, Donghee Kim · 2026 · Expert Review of Gastroenterology & Hepatology
  52. Association between the triglyceride-glycated hemoglobin index and diabetes risk among patients with Non-alcoholic fatty liver disease: A longitudinal cohort study
    Cuimei Wei, Changchun Cao, XU Zengxin, Gang Chen, Wenjing Liu, Miao Zhang, Haofei Hu, Shanghua Xu · 2026 · PLoS ONE
  53. Metabolic dysfunction profiles identify heterogeneous hepatocellular carcinoma risk in MASLD-associated advanced fibrosis
    Mario Romeo, Marcello Dallio, Carmine Napolitano, Fiammetta Di Nardo, Alessandro Federico · 2026 · Journal of Hepatology
  54. Regulators of Genetic Risk for the Progression of Non-alcoholic Fatty Liver Disease to Hepatocellular Carcinoma: Reconstruction of Transcriptional Network and Signature-Based Metabolic Profiling
    Dora Lucía Vallejo-Ardila, Marco Antônio De Bastiani, Diego Salazar · 2022 · Interdisciplinary cancer research
  55. Identifying High-Risk Patients With Nonalcoholic Fatty Liver Disease
    Jae Seong No, Adam P. Buckholz, Catherine Young Han, Steven Matthews, Brett E. Fortune, Tibor I. Krisko, Carolyn A. Newberry, Sonal Rajesh Kumar · 2022 · Journal of Clinical Gastroenterology
  56. Contrast-enhanced ultrasound for hepatocellular carcinoma detection and diagnosis in the context of nonalcoholic fatty liver disease
    Kevin George King, Jena N. Depetris, Maitraya K. Patel, Steven S. Raman, David Lu · 2023 · Hepatoma Research
  57. Impact and usefulness of the transition to the new MAFLD classification for non-B, non-C HCC: a retrospective cohort study
    Yusuke Johira, Takashi Nakahara, Takahiro Kinami, Shintaro Yamasaki, Masanari Kosaka, Yuki Shirane, Ryoichi Miura, Serami Murakami, Shigeki Yano, Kei Amioka et al. · 2023 · BMC Gastroenterology
  58. Characterization of an At-Risk Population for Nonalcoholic Fatty Liver Disease (NAFLD) in a Primary Care Setting Along the U.S.–Mexico Border
    Lindsay Spitz, Stefan Saadiq, Navkiran K. Shokar, Marc J. Zuckerman, Nancy A. Casner, Roy Valenzuela, Jennifer J. Salinas · 2024 · Journal of Transcultural Nursing
  59. Research Progress on Multidisciplinary Intervention for Metabolic Dysfunction-Associated Steatotic Liver Disease and Related Liver Cancer
    Yu Zhang, Chao Xu · 2024 · Journal of Biosciences and Medicines
  60. Changes in general and central fatness are associated with hepatocellular carcinoma: A Korean nationwide longitudinal study
    Mi Na Kim, Kyungdo Han, Juhwan Yoo, Yeonjung Ha, Young Eun Chon, Ju Ho Lee, Seong Gyu Hwang · 2021 · International Journal of Cancer
  61. Non-Alcoholic Fatty Liver Disease: How to Avoid Mistakes in Patient’s Curation
    Maria A. Livzan, Кролевец Татьяна Сергеевна, T.V. Kostoglod Kostoglod, А.V. Kostoglod Kostoglod · 2021 · Effective Pharmacotherapy
  62. Actualización del abordaje farmacológico de la enfermedad Esteatósica Asociada a Disfunción Metabólica
    Xavier Ramon, Paola Verónica Orellana Bernal · 2023 · Salud ConCiencia
  63. Acetyl-CoA metabolism drives epigenome change and contributes to carcinogenesis risk in fatty liver disease
    Gabriella Assante, Sriram Chandrasekaran, Stanley Ng, Aikaterini Tourna, Carolina H. Chung, Kowsar A. Isse, Céline Filippi, Anil Kumar Dhawan, Mo Liu, Steve Rozen et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  64. Editorial: Cardiometabolic criteria matters in MASLD
    Margaret Li Peng Teng, Mark Dhinesh Muthiah, Daniel Q. Huang · 2024 · Alimentary Pharmacology & Therapeutics
  65. Identification of Fatty acid metabolism-Related Genes in the Progression from Non-Alcoholic Fatty Liver to Nonalcoholic fatty liver disease
    Xuancheng Xie, Tao Xiong, Yue Zhai, Xingli Liu, Wei Song, Meng Qiu Gao, Xiao He, Hongjie Fan, Gang Wang · 2024 · Research Square
  66. Alcohol Consumption in Non-Alcoholic Fatty Liver Disease: Safety and Disease Overlap
    Sheela S. Reddy · 2020 · Current Hepatology Reports
  67. Risk Factors of Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
    Wenpei Guo, Lixin Liu · 2021 · Research Square
  68. Doença hepática gordurosa não alcoólica (DHGNA) e síndrome dos ovários policísticos (SOP): associação do polimorfismo no gene da patatin-like phospholipase domain containing 3 (PNPLA3) e alterações endócrinas e metabólicas
    Amanda Medeiros Recuero · 2022
  69. Glycemic control, body weight reduction, or glucose-lowering therapy in diabetic patients: What is better for the liver?
    Salvatore Petta · 2023 · Nutrition Metabolism and Cardiovascular Diseases
  70. Clinical characteristics of hospitalized patients with metabolic-associated fatty liver disease–related liver cancer: data from a single center, 2010–2019
    Guishuang Wang, Hong Zhao, Lei Sun, Gang Wan, Wen Xie · 2023 · Therapeutic Advances in Chronic Disease
  71. Linear age-course association between non-alcoholic fatty liver disease, components of metabolic syndrome, and mortality
    Xinyu Zhao, Shuohua Chen, Xiao Wang, Zhenyu Wang, Yuanyuan Sun, Chenlu Yang, Mengyi Zheng, Yanhong Wang, Wei Liao, Shouling Wu et al. · 2023 · medRxiv
  72. Cardio-oncology: new insights into association and interaction between cardiovascular disease and cancer
    Canxia Shi · 2023
  73. Effect Analysis of QCT in the Diagnosis of Fatty Liver in Perimenopausal Women
    静 雷 · 2024 · Advances in Clinical Medicine
  74. Reply to: “Longitudinal changes in fatty liver index are associated with risk of hepatocellular carcinoma: A nationwide cohort study in Korea”
    George T. Cholankeril, Fasiha Kanwal · 2024 · Journal of Hepatology
  75. Progress in the Study of Risk Factors Associated with Primary Liver Cancer
    古门勒 乌日 · 2024 · Advances in Clinical Medicine
  76. Additional file 4 of Acetyl-CoA metabolism drives epigenome change and contributes to carcinogenesis risk in fatty liver disease
    Gabriella Assante, Sriram Chandrasekaran, Stanley Ng, Aikaterini Tourna, Carolina H. Chung, Kowsar A. Isse, Jasmine L. Banks, Ugo Soffientini, Céline Filippi, Anil Kumar Dhawan et al. · 2022 · Figshare
  77. Additional file 3 of Acetyl-CoA metabolism drives epigenome change and contributes to carcinogenesis risk in fatty liver disease
    Gabriella Assante, Sriram Chandrasekaran, Stanley Ng, Aikaterini Tourna, Carolina H. Chung, Kowsar A. Isse, Jasmine L. Banks, Ugo Soffientini, Céline Filippi, Anil Kumar Dhawan et al. · 2022 · Figshare
  78. Additional file 1 of Acetyl-CoA metabolism drives epigenome change and contributes to carcinogenesis risk in fatty liver disease
    Gabriella Assante, Sriram Chandrasekaran, Stanley Ng, Aikaterini Tourna, Carolina H. Chung, Kowsar A. Isse, Jasmine L. Banks, Ugo Soffientini, Céline Filippi, Anil Kumar Dhawan et al. · 2022 · Figshare
  79. Editorial: Cardiometabolic criteria matters in MASLD —Authors' reply
    Nobuharu Tamaki, Takefumi Kimura, Shun‐ichi Wakabayashi, Takeji Umemura, Namiki Izumi, Rohit Seth Loomba, Masayuki Kurosaki · 2024 · Alimentary Pharmacology & Therapeutics
  80. Association of Comorbidity Duration with the Occurrence and Prognosis of Steatotic Liver Disease
    Hyunji Sang, Ji Hyae Lim, Ha Il Kim · 2024 · Digestive Diseases and Sciences
  81. Cirrhose métabolique : une entité en plein essor
    Vlad Ratziu · 2024 · Bulletin de l Académie Nationale de Médecine
  82. Risk Stratification of Metabolic Risk Factors and Statin Use Associated With Liver and Nonliver Outcomes in Chronic Hepatitis B
    Xinrong Zhang, Vy H. Nguyen, Leslie Yeeman Kam, Scott Douglas Barnett, Linda L Henry, Ramsey C Cheung, Mindie H. Nguyen · 2024 · The Journal of Infectious Diseases
  83. The Analysis Study of Association of Type 2 Diabetes Mellitus and Hepatocellular Carcinoma : A Comprehensive Systematic Review
    Muhammad Ilham Wira Tri Putra, Asra Dewita Namora Harahap · 2024 · The Indonesian Journal of General Medicine
  84. Metabolic Dysfunction-associated Steatotic Liver Disease–related Hepatocellular Carcinoma: Current Research Insights
    Ho Soo Chun, Minjong Lee, Tae Hun Kim · 2024 · Journal of Digestive Cancer Research
  85. The significance of metabolism-associated steatotic liver disease and its treatment
    Adam Vašura, Evžen Machytka, Marek Bužga, Jitka Macháčková, Jan Král · 2025 · Vnitřní lékařství
  86. Rationale for choosing antihypertensive therapy in a patient with NAFLD and arterial hypertension
    Мехтиев Сабир Насрединович, О. А. Мехтиева, Берко Олеся Михайловна · 2025 · Экспериментальная и клиническая гастроэнтерология
  87. A Gastroenterologist’s Approach to Improving Metabolic Health in MASLD
    Iyiad Alabdul Razzak, Imad Alabdul Razzak, Mazen Noureddin, Hirsh D. Trivedi · 2025 · Journal of Clinical Gastroenterology
  88. Relationship between glucagon and metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus
    Yi Xin Sun, Ping Hsin Huang, Xiaoqin Zhao, Zhuqi Tang, Tongtong Xu, Xin-Wei Wang, Zong-Xian Qi, Wei-Rong Lin, Li Minyou, Yunjuan Gu · 2025 · World Journal of Hepatology
  89. Non-alcoholic fatty liver disease and hypertension: a bidirectional, mutually aggravating relationship
    Leonid Borisovich Lazebnik, Светлана Владимировна Туркина · 2024 · Экспериментальная и клиническая гастроэнтерология
  90. Should Hepatocellular Carcinoma Surveillance Be Performed in Patients with Noncirrhotic Metabolic Dysfunction-Associated Steatohepatitis?
    Rubén Hernáez, Fasiha Kanwal · 2025 · Springer eBooks
  91. Number of metabolic syndrome traits adds little to prediction of major adverse liver outcomes on top of FIB-4 in patients with type 2 diabetes
    Emilie Toresson Grip, Ying Shang, Helena Skröder, Angelo Modica, Oskar Ström, Fady Y. Ntanios, Soffia Guðbjörnsdóttir, Hannes Hagström · 2025 · Diabetes Epidemiology and Management
  92. Components of cardiometabolic risk factors predict liver-related events in patients cured of hepatitis C Virus
    Wei‐Fan Hsu, Hsueh‐Chou Lai, Hung‐Wei Wang, Sheng‐Hung Chen, Wen‐Pang Su, Hung‐Yao Chen, Guan‐Tarn Huang, Cheng‐Yuan Peng · 2025 · Journal of Microbiology Immunology and Infection
  93. Reactive oxygen species (ROS) and late-stage cancer (Cancer metastasis)
    Milena Krajnović, Snežana Jovanović-Ćupić, Bojana Kožik, Ana Božović · 2025 · Elsevier eBooks
  94. Foie métabolique
    Antonio Saviano, Lawrence Serfaty · 2025 · EMC - Hépatologie
  95. Beyond biomarkers: An integrated traditional Chinese medicine-machine learning approach predicts hepatic steatosis in high metabolic risk populations
    Yanchun Guo, Hong Ye, Li Huang, Xiaowei Xu, Jingqi Sun, Kangkang Ji, Chao-Nian Li · 2025 · World Journal of Gastroenterology
  96. Association of metabolic risk factors with the severity of hepatic fibrosis and steatosis in metabolic dysfunction-associated fatty liver disease patients
    Maha Elsabaawy, Warda Othman, Sameh Abdel Mawgoud Afify, Tamer Samir, Madiha Naguib · 2025 · Egyptian Liver Journal
  97. Highlighting the relevance of a multidisciplinary approach in metabolic-asociated steatotic liver disease (MASLD)
    Carmen Lara‐Romero, Miguel Angel Fernández-Gómez, Franz Martı́n, Luis Castilla‐Guerra, Jesús Funuyet‐Salas, Genoveva Berná, Raquel Millán-Domínguez, Manuel Romero‐Gómez · 2025 · Expert Review of Gastroenterology & Hepatology
  98. Additional file 1 of Impact and usefulness of the transition to the new MAFLD classification for non-B, non-C HCC: a retrospective cohort study
    Yusuke Johira, Takashi Nakahara, Takahiro Kinami, Shintaro Yamasaki, Masanari Kosaka, Yuki Shirane, Ryoichi Miura, Serami Murakami, Shigeki Yano, Kei Amioka et al. · 2024 · Figshare
  99. Additional file 1 of USP13 ameliorates nonalcoholic fatty liver disease through inhibiting the activation of TAK1
    Tang, Min, Han Cao, Yunqin Ma, Yao, Shuangshuang, Wei, Xiaohui, Yijiong Tan, liu, Fang, Peng, Yongde, Fan, Nengguang · 2024 · Figshare
  100. Additional file 2 of Acetyl-CoA metabolism drives epigenome change and contributes to carcinogenesis risk in fatty liver disease
    Gabriella Assante, Chandrasekaran, Sriram, Ng, Stanley, Aikaterini Tourna, Carolina H. Chung, Kowsar A. Isse, Jasmine L. Banks, Ugo Soffientini, Céline Filippi, Dhawan, Anil et al. · 2022 · Figshare